Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

Effectiveness Analysis ◽

Prevention And Treatment

Cost effectiveness analysis of a next generation risk assessment score for cardiovascular disease

Journal of Medical Economics ◽

10.3111/13696998.2013.869500 ◽

2013 ◽

Vol 17 (2) ◽

pp. 132-141

Author(s):

Evangelos Hytopoulos ◽

Martin L. Lee ◽

Michael Beggs ◽

Cynthia French ◽

Kuo Bianchini Tong

Keyword(s):

Cardiovascular Disease ◽

Risk Assessment ◽

Cost Effectiveness ◽

Next Generation ◽

Assessment Score ◽

A Framework for the Cost-Effectiveness Analysis of Novel Biomarker Testing in Cardiovascular Disease

Value in Health ◽

10.1016/j.jval.2017.08.040 ◽

2017 ◽

Vol 20 (9) ◽

pp. A404-A405

Author(s):

CN Kohli-Lynch ◽

K Boyd ◽

A Briggs ◽

C Delles

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Biomarker Testing ◽

The Cost

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease

Diabetes Therapy ◽

10.1007/s13300-019-00701-3 ◽

2019 ◽

Vol 10 (6) ◽

pp. 2153-2167 ◽

Cited By ~ 7

Author(s):

Mafalda Ramos ◽

Volker Foos ◽

Anastasia Ustyugova ◽

Nikco Hau ◽

Pranav Gandhi ◽

...

Keyword(s):

Type 2 Diabetes ◽

Cardiovascular Disease ◽

Cost Effectiveness ◽

Cardiovascular Outcome ◽

Cardiovascular Outcome Trials ◽

A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?

Genetics in Medicine ◽

10.1038/s41436-020-00995-w ◽

2020 ◽

Author(s):

Ye Zhu ◽

James P. Moriarty ◽

Kristi M. Swanson ◽

Paul Y. Takahashi ◽

Suzette J. Bielinski ◽

...

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

Disease Management ◽

Model Based ◽

Panel Testing ◽

PCV33 A COST-EFFECTIVENESS ANALYSIS OF LOW-DOSE ASPIRIN IN THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN FOUR EUROPEAN COUNTRIES

Value in Health ◽

10.1016/s1098-3015(10)67445-1 ◽

2005 ◽

Vol 8 (6) ◽

pp. A98-A99

Author(s):

M Lamotte ◽

L Annemans ◽

T Evers ◽

M Kubin

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

Primary Prevention ◽

Low Dose ◽

Prevention Of Cardiovascular Disease

European Countries ◽

Dose Aspirin ◽

Effectiveness Analysis ◽

Low Dose Aspirin ◽

Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease - A cost-effectiveness analysis

BMC Cardiovascular Disorders ◽

10.1186/1471-2261-12-26 ◽

2012 ◽

Vol 12 (1) ◽

Cited By ~ 10

Author(s):

Torbjørn Wisløff ◽

Randi M Selmer ◽

Sigrun Halvorsen ◽

Atle Fretheim ◽

Ole F Norheim ◽

...

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

Primary Prevention ◽

Antihypertensive Drugs ◽

Prevention Of Cardiovascular Disease

Effectiveness Analysis ◽

O117 Cardiovascular disease and impoverishment averted due to a salt reduction program in South Africa: an extended cost-effectiveness analysis

Global Heart ◽

10.1016/j.gheart.2014.03.1328 ◽

2014 ◽

Vol 9 (1) ◽

pp. e31-e32 ◽

Cited By ~ 1

Author(s):

David Watkins ◽

Zachary Olson ◽

Stephane Verguet ◽

Dean Jamison ◽

Rachel Nugent

Keyword(s):

South Africa ◽

Cardiovascular Disease ◽

Cost Effectiveness ◽

Salt Reduction ◽

Effectiveness Analysis ◽

Reduction Program

Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina

BMC Public Health ◽

10.1186/1471-2458-10-627 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 47

Author(s):

Adolfo Rubinstein ◽

Lisandro Colantonio ◽

Ariel Bardach ◽

Joaquín Caporale ◽

Sebastián García Martí ◽

...

Keyword(s):

Risk Factors ◽

Cardiovascular Disease ◽

Cost Effectiveness ◽

Modifiable Risk Factors ◽

Effectiveness Analysis ◽

Preventative Interventions

PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE

Value in Health ◽

10.1016/j.jval.2018.09.778 ◽

2018 ◽

Vol 21 ◽

pp. S130 ◽

Cited By ~ 1

Author(s):

M. Carrasco Perez ◽

N. Male ◽

M. Serra Burriel ◽

E. Pfarr ◽

A. Kansal

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

National Health Service ◽

Health Service ◽

Indirect Cost ◽

National Health ◽

Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy

Value in Health ◽

10.1016/j.jval.2017.08.464 ◽

2017 ◽

Vol 20 (9) ◽

pp. A480-A481 ◽

Cited By ~ 3

Author(s):

S Iannazzo ◽

E Mannucci ◽

O Reifsnider ◽

AP Maggioni

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽